Program Official
Principal Investigator
John A
Ellerton
Awardee Organization
Southern Nevada Cancer Research Fdn
United States
Fiscal Year
2024
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date
NIH RePORTER
For more information, see NIH RePORTER Project 5UG1CA189829-11
NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)
The Nevada Cancer Research Foundation (NCRF) was established in 1983 to conduct cancer research. The NCRF main office is located in Las Vegas with satellite offices in Reno and Carson City, Nevada and Arroyo Grande, California and Port Huron, Michigan. Over 80% of the oncologists, hematologists and radiation oncologists in Nevada are investigator members of the NCRF and participate in NCI clinical trials and projects. NCRF’s primary mission is to provide quality and state-of-the-art cancer treatment in Nevada through participation in active cancer research studies for the residents of Nevada through the participation of the local physicians and health care providers. NCRF also has as part of its mission the provision of high quality, timely data to the NCI Community Oncology Research Program (NCORP) Research Bases in a research environment that sets the highest standards for the safety and welfare of the clinical trials’ participants. NCRF will continue to enroll patients/participants on NCI clinical trials and plans to exceed the required annual 80 new unique patient/participant accruals evenly distributed between cancer control, prevention, and screening/post-treatment surveillance trials, and treatment and imaging trials, respectively that is required for participation in NCORP. NCRF also plans to participate in at least three cancer care delivery protocols annually and to continue to participate in bio-specimen collection for biobanks that serve as scientific resources for the NCORP Research Bases. NCRF plans to actively work with the NCI to develop an integrated community-based research network in order to reduce the cancer incidence, morbidity, and mortality in Nevada by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management rehabilitation, quality of life, and continuing care technology. NCRF will involve NCRF staff and physicians in the scientific and educational activities of the Research Bases and will participate in studies to enhance participation of racial/ethnic and other underserved populations underrepresented in research. To accomplish these goals, the NCRF opens the program for state-wide participation, thereby providing access for participation to the residents of Nevada.
Publications
- Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, Cella D, Sweeney CJ, ECOG-ACRIN E3805 Investigators. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. The Prostate. 2022 Sep;82(12):1176-1185. Epub 2022 May 10. PMID: 35538398
- Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 1;36(4):326-332. Epub 2017 Nov 14. PMID: 29136387
- Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA oncology. 2017 Aug 1;3(8):1043-1050. PMID: 28208174
- Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 May 1;27(9):2435-2441. Epub 2021 Feb 10. PMID: 33568346
- Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 May 20;35(15):1695-1703. Epub 2017 Apr 6. PMID: 28384065
- Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature medicine. 2020 Oct;26(10):1564-1568. Epub 2020 Oct 5. PMID: 33020646
- Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology. 2018 Jan;19(1):101-114. Epub 2017 Nov 20. PMID: 29169877
- Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019 Nov 1;125(21):3790-3800. Epub 2019 Jul 10. PMID: 31290996
- Chou SS, Romanoff J, Lehman CD, Khan SA, Carlos R, Badve SS, Xiao J, Corsetti RL, Javid SH, Spell DW, Han LK, Sabol JL, Bumberry JR, Gareen IF, Snyder BS, Gatsonis C, Wagner LI, Wolff AC, Miller KD, Sparano JA, Comstock CE, Rahbar H. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). Radiology. 2021 Oct;301(1):66-77. Epub 2021 Aug 3. PMID: 34342501
- Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46. Epub 2015 Aug 5. PMID: 26244877